Vol. 39 No. 4 (2022): August
Review Article

Hepatitis E virus

PDF (Español (España))
  • Leidy Maritza Sánchez González,
  • Ana Lucía Reyes Perea,
  • Astrid Milena Bedoya
Leidy Maritza Sánchez González
Universidad de Antioquia, Medellín
Bio
Ana Lucía Reyes Perea
Universidad de Antioquia, Medellín
Bio
Astrid Milena Bedoya
Universidad de Antioquia, Medellín
Bio

Published 2022-10-04

Keywords

How to Cite

1.
Sánchez González LM, Reyes Perea AL, Bedoya AM. Hepatitis E virus. Rev. Chilena. Infectol. [Internet]. 2022 Oct. 4 [cited 2026 Jun. 2];39(4). Available from: https://revinf.cl/index.php/revinf/article/view/1540

Copyright (c) 2022 Leidy Maritza Sánchez González, Ana Lucía Reyes Perea, Astrid Milena Bedoya

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

The hepatitis E virus (HEV) is one of the main etiological agents of enteric hepatitis in the world. In developing countries its seroprevalence ranges from 20 to 50% and in developed countries from 4.4% to 21%. Clinically, cases of HEV infection in immunocompetent individuals present as self-limited acute viral hepatitis; conversely, in pregnant women, transplanted individuals, and individuals living with the human immunodeficiency virus (HIV), the infection can manifest as chronic and severe hepatitis. In Latin America, only Brazil and Argentina report figures for individuals living with HIV. More studies are required in our region to determine the prevalence of HEV in immunosuppressed individuals, blood donors, and the general population to adopt measures that guarantee timely diagnosis, access to care, and control of transmission.

PDF (Español (España))